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Abstract
Recent genetic and cell biological studies illustrate the importance
of active transforming growth factor-β signaling in preventing the
proliferation of estrogen receptor-positive cells in the normal
mammary gland, and suggest how the loss of this inhibition may be
important in early breast cancer progression.
A recent report by Ewan and colleagues [1] sheds some light
on the mechanism by which steroid receptor-positive cells
are prevented from proliferating in the normal adult mammary
gland by the expression of activated transforming growth
factor (TGF)-β. This report is an extension of earlier studies
by the same authors that first demonstrated the ability to
detect latent versus activated TGF-β expression in situ [2].
Steroid receptor expression is often used as a prognostic
indicator and target of endocrine therapy in breast cancer.
However, our understanding of the normal distribution and
regulation of estrogen receptor (ER)-α and progesterone
receptor (PR) expression is still evolving. In normal adult
mammary glands from humans, rats, mice, or cows, steroid
receptor-positive cells are heterogeneously located in luminal
epithelial cells throughout the ducts and rarely co-localize
with markers of proliferation [3-6]. Growth factors expressed
in steroid receptor-positive cells act on neighboring cells to
induce proliferation in a paracrine fashion. An elegant series
of experiments by Cathrin Brisken and her colleagues [7,8]
have established the ability of estrogen receptor-positive or
progesterone receptor-positive cells to rescue ER-null and
PR-null cells, respectively, in chimeric fat-pad transplantation
experiments. However, a key question in mammary gland
development is what prevents ER/PR-positive cells from
dividing and why this proliferative block is lost during breast
cancer progression. For example, ER/PR-positive cells are
often proliferative in mouse models of mammary hyperplasia
and in precancerous lesions of the human breast, such as
ductal carcinoma in situ, suggesting a switch from a
paracrine to an autocrine response to proliferative stimuli
[9,10].
TGF-β is a potent inhibitor of epithelial cell proliferation, but
little is known about the process involved in activating the
latent form secreted by most cells [11]. The relationship
between TGF-β activation, ER-α expression, and proliferation
were the focus of the recent study by Ewan and colleagues
[1]. Using immunostaining to detect the activated form of
TGF-β during estrus, they were able to show that the cells
positive for active TGF-β also expressed the downstream
effector R-SMAD in the nucleus, providing evidence that
TGF-β acts in an autocrine manner. Co-immunostaining
experiments using double immunofluorescence were
performed to show that ER-α co-localized with nuclear R-
SMAD staining and activated TGF-β co-localized with both
ER-α and PR, supporting their hypothesis that TGF-β
activation might inhibit the ability of ER/PR-expressing cells to
respond to ovarian hormone-induced proliferation.
Mice heterozygous for the TGF-β1 allele have a 90%
reduction in the amount of TGF-β1 protein expressed [12].
Using mammary glands from these mice, the expression of
ER-α and Ki67, a marker of proliferation, was assessed.
Mammary glands from TGF-β1+/– mice exhibited a 24-fold
increase in proliferation, and co-localization of ER-α and Ki67
was increased 16-fold. The same results were found when
this analysis was performed on outgrowths after transplan-
tation of TGF-β1+/– mammary epithelial cells, suggesting that
epithelial, rather than stromal, TGF-β is responsible for
keeping ER/PR-positive cells from proliferating. After ovariec-
tomy, no ER-α/Ki67 double-positive cells were observed in
TGF-β1+/– glands in the absence of ovarian hormones. Only
when estrogen and progesterone were added back was
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there a 17-fold increase in double-labeled cells. Although a
loss of TGF-β expression resulted in increased proliferation in
the presence of ovarian hormones, the expression of
constitutively active TGF-β was able to override hormone-
induced proliferation. Mammary glands from mouse mammary
tumor virus (MMTV)–TGF-β transgenic mice displayed sixfold
fewer ER-α/Ki67 double-positive cells than wild-type glands
at estrus.
Fewer proliferating ER-α-positive cells are detected in the
mammary glands of parous humans or rats than in glands
from nulliparous subjects [4,13]. To test whether TGF-β has a
function in this phenomenon, parous glands from TGF-β1+/–
mice were analyzed for ER-α and Ki67 co-localization. The
frequency of double-labeled cells in parous glands from
TGF-β1+/– mice was fourfold that in parous wild-type mice,
indicating that TGF-β is also involved in inhibiting the
proliferation of ER-α-positive cells in parous animals. These
data also fit with the findings of Boulanger and colleagues,
who demonstrated that TGF-β-positive cells from parous
glands did not contribute to repopulating the gland,
suggesting that they were incapable of ‘expansive cellular
proliferation’ and stem cell self-renewal [14]. TGF-β expres-
sion has also been shown to increase mammary stem cell
senescence and to inhibit MMTV-induced mammary
carcinogenesis [15]. Finally, the effect of TGF-β1 depletion
was analyzed during puberty, a time of rapid proliferation in
the terminal end bud structures. Loss of TGF-β1 did not
increase the proliferation of ER-α-positive cells in either the
terminal end buds or ducts, although proliferation was
increased overall. This supports the idea that proliferation of
ER/PR-positive cells during puberty is regulated differently
from that in the adult gland.
These data advance our understanding of how steroid
receptor-positive cells might be prevented from proliferating
in the normal mammary gland, and how this process might
become deregulated in breast cancer progression. Further
evidence for the role of TGF-β in regulating the proliferation
of steroid receptor-expressing cells comes from our studies
of CCAAT-enhancer-binding protein (C/EBP)β-null mice.
Mammary glands from these mice show increased numbers
of ER/PR-positive cells and a 10-fold decrease in proliferation
[5]. Recently, we discovered that these C/EBPβ-null glands
also display a significant increase in activated TGF-β along
with increased downstream Smad2 expression and signaling
[16]. Another downstream target of TGF-β is the cyclin-
dependent kinase inhibitor, p27Kip1, which in turn affects the
activity of other cell cycle components such as cyclin E and
cyclin-dependent kinase (cdk)2 [17]. All of these molecules
were altered in C/EBPβ-null glands, resulting in decreased
cyclin E expression, loss of cdk2 kinase activity, increased
p27 stability and decreased levels of cdc25A phosphatase
activity.  These studies with mouse models have led us to
speculate that loss of active TGF-β expression in
precancerous  breast lesions might result in increased
expression or stability of cdc25A and increased cyclin
E/cdk2 activity in steroid receptor-positive cells, allowing
them to proliferate. In support of this hypothesis, cdc25A was
recently shown to be induced by genomic and non-genomic
actions of estrogen in breast cancer cells [18,19]. The
expression of cdc25a is also regulated both transcriptionally
Figure 1
A hypothetical model of paracrine versus autocrine signaling in mammary epithelial cells. Normal mammary epithelial cells expressing estrogen
receptor (ER)α and progesterone receptor (PR) are restrained from proliferating, mediated by the growth-inhibitory actions of transforming growth
factor (TGF)-β signaling, active in this population. The steroid receptor-positive cells secrete local-acting growth factors to induce neighboring cells
to divide in a paracrine fashion. In early breast cancer progression, this normal paracrine mechanism may switch to an autocrine loop, allowing
steroid receptor-positive cells to proliferate, possibly through the downregulation of active TGF-β signaling, leading to an upregulation of cell-cycle
molecules such as cdc25A, cyclin E and cyclin-dependent kinase (cdk)2. IGF, insulin-like growth factor.Page 3 of 3
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and post-transcriptionally by TGF-β, and thus may be a useful
downstream indicator of active TGF-β signaling [20]. p27 has
also been proposed as a prognostic marker in breast cancer
[21]. However, the subcellular localization and phosphory-
lation state of the protein are critical in regulating its activity,
and it would, therefore, be problematic to assess these
changes in clinical samples. A hypothetical model summariz-
ing these results with regard to breast cancer progression is
shown in Figure 1.
Conclusion
Critical questions that still need to be addressed are what
mechanisms are responsible for the activation of TGF-β only
in the ER/PR-positive cells, and how the patterning of cells
expressing steroid receptors is established both in normal
development and breast cancer. With the availability of
appropriate immunological reagents, these hypotheses
should be tested with patient samples, to determine whether
these markers will provide a method for predicting which
patients with ductal carcinoma in situ have a higher likelihood
of progression to infiltrating ductal carcinoma.
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